Alain Munoz
Chairman at ACTICOR BIOTECH SAS
Net worth: 1 M $ as of 2024-03-30
Network origin in Alain Munoz first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 61 | |
| Public Company | Biotechnology | 20 | |
Novagali Pharma SA
 Novagali Pharma SA Pharmaceuticals: MajorHealth Technology Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France.
16
| Extinct | Pharmaceuticals: Major | 16 |
| Subsidiary | Pharmaceuticals: Major | 15 | |
12
| Public Company | Pharmaceuticals: Major | 12 |
Vivalis SA
 Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France.
11
| Extinct | Pharmaceuticals: Other | 11 |
| Public Company | Biotechnology | 11 | |
Genticel SA
 Genticel SA BiotechnologyHealth Technology Genticel SA operates as a clinical stage biotechnology company, which focuses on the development of immunotherapies designed to fight infectious diseases and cancer. The company was founded by Bénédikt Timmerman and Ludovic de Meeus d'Argenteuil on October 15, 2001 and is headquartered in Labège, France.
9
| Extinct | Biotechnology | 9 |
Auris Medical Holding AG /Old/
 Auris Medical Holding AG /Old/ Medical SpecialtiesHealth Technology Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its products portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland.
8
| Extinct | Medical Specialties | 8 |
Auris Medical AG
 Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland.
4
| Subsidiary | Medical Specialties | 4 |
Intercell Austria AG
3
| Private Company | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Alain Munoz via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| TDC A/S | Major Telecommunications | Corporate Officer/Principal Corporate Officer/Principal | |
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Biotechnology | Director/Board Member Compliance Officer | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Public Communications Contact Director/Board Member | |
| SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| AUXILIUM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Compliance Officer | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | President Director/Board Member Director/Board Member Corporate Officer/Principal | |
| CHIASMA, INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
| TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member | |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
| BIOINVENT INTERNATIONAL AB | Biotechnology | Chairman Director/Board Member | |
| University of Oxford | College/University | Undergraduate Degree Undergraduate Degree | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member Investor Relations Contact | |
| OREXO AB | Pharmaceuticals: Major | Director/Board Member Chairman | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| University of Aarhus | College/University | Corporate Officer/Principal Masters Business Admin Undergraduate Degree | |
| INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
American Bar Association
 American Bar Association Miscellaneous Commercial ServicesCommercial Services American Bar Association provides legal services. It provides law school accreditation, continuing legal education, legal information and other services to assist legal professionals. The firm has members which include judges, court administrators, law professors, and non-practicing attorneys. The company was founded on August 21, 1878 and is headquartered in Chicago, IL. | Miscellaneous Commercial Services | Chairman Corporate Officer/Principal | |
| DBV TECHNOLOGIES | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| University of Lund | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| ESSEC Business School | College/University | Graduate Degree Masters Business Admin | |
| École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin Masters Business Admin | |
| University of Strasbourg | College/University | Doctorate Degree Doctorate Degree | |
| TXCELL | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| VOLUNTIS S.A. | Packaged Software | Director/Board Member Director/Board Member Director/Board Member | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Chairman Director/Board Member | |
| Weill Cornell Medical College | College/University | Corporate Officer/Principal Doctorate Degree | |
Minka Therapeutics SA
 Minka Therapeutics SA Pharmaceuticals: MajorHealth Technology Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
Kurma Partners SA
 Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor Private Equity Investor | |
| EGETIS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member Founder | |
| VALNEVA | Biotechnology | Corporate Officer/Principal Chairman Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Executive Officer | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Chief Executive Officer | |
| Harvard Business School | College/University | Masters Business Admin Graduate Degree Masters Business Admin | |
| Columbia University College of Physicians & Surgeons | College/University | Doctorate Degree Corporate Officer/Principal | |
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Investment Managers | Consultant / Advisor Consultant / Advisor | |
| Roche SAS | President Corporate Officer/Principal | ||
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Founder Director/Board Member Compliance Officer Director/Board Member Director/Board Member Director/Board Member Director/Board Member General Counsel Public Communications Contact Human Resources Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| GENKYOTEX SA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
DNA Script SAS
 DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member Director/Board Member | |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PHAXIAM THERAPEUTICS S.A. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chairman Director/Board Member |
Statistics
International
| France | 22 |
| United States | 10 |
| Denmark | 7 |
| Sweden | 5 |
| United Kingdom | 5 |
Sectoral
| Health Technology | 32 |
| Consumer Services | 14 |
| Finance | 3 |
| Communications | 2 |
| Commercial Services | 2 |
Operational
| Director/Board Member | 573 |
| Corporate Officer/Principal | 199 |
| Chairman | 153 |
| Independent Dir/Board Member | 142 |
| Chief Executive Officer | 105 |
Most connected contacts
| Insiders | |
|---|---|
| Peter James Arthur Benson | 58 |
| Antoine Papiernik | 48 |
| Philippe Peltier | 45 |
| Frédéric Grimaud | 33 |
| Alf Gunnar Martin Nicklasson | 31 |
| Patrick Volkert Vink | 30 |
| Alain Parthoens | 29 |
| Catherine Moukheibir | 29 |
| Gerald Heinz Möller | 29 |
| Rémi Droller | 29 |
| Jeffrey Berkowitz | 26 |
| Didier Hoch | 24 |
| Rosemary Crane | 23 |
| Berndt A. E. Modig | 23 |
| Leonard Kruimer | 22 |
- Stock Market
- Insiders
- Alain Munoz
- Company connections
